Search

Your search keyword '"Elisa Champanhet"' showing total 2 results
Start Over Author "Elisa Champanhet"
2 results on '"Elisa Champanhet"'

1. Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality

Author

Noor A. M. Bakker, Hannah Garner, Ewald van Dyk, Elisa Champanhet, Chris Klaver, Maxime Duijst, Leonie Voorwerk, Iris Nederlof, Rosie Voorthuis, Marte C. Liefaard, Marja Nieuwland, Iris de Rink, Onno B. Bleijerveld, Hendrika M. Oosterkamp, Lodewyk F. A. Wessels, Marleen Kok, and Karin E. de Visser

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Cancer disrupts intratumoral innate-adaptive immune crosstalk, but how the systemic immune landscape evolves during breast cancer progression remains unclear. We profiled circulating immune cells in stage I–III and stage IV triple-negative breast cancer (TNBC) patients and healthy donors (HDs). Metastatic TNBC (mTNBC) patients had reduced T cells, dendritic cells, and differentiated B cells compared to non-metastatic TNBC patients and HDs, partly linked to prior chemotherapy. Vδ1 γδ T cells from mTNBC patients produced more IL17 than those from HDs. Chemotherapy-naïve mTNBC patients showed increased classical monocytes and neutrophils. Transcriptional, proteomic, and functional analyses revealed that neutrophils in mTNBC exhibited enhanced migratory capacity, elevated granule proteins, and higher ROS production. Some immune changes, such as reduced non-switched B cells and heightened neutrophil migration, were evident in earlier TNBC stages. This study comprehensively maps systemic immunity in TNBC, guiding future research on patient stratification and immunomodulation strategies.

Published
2025
Full Text
View/download PDF

2. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer

Author

Leonie Voorwerk, Olga I. Isaeva, Hugo M. Horlings, Sara Balduzzi, Maksim Chelushkin, Noor A. M. Bakker, Elisa Champanhet, Hannah Garner, Karolina Sikorska, Claudette E. Loo, Inge Kemper, Ingrid A. M. Mandjes, Michiel de Maaker, Jasper J. L. van Geel, Jorianne Boers, Maaike de Boer, Roberto Salgado, Marloes G. J. van Dongen, Gabe S. Sonke, Karin E. de Visser, Ton N. Schumacher, Christian U. Blank, Lodewyk F. A. Wessels, Agnes Jager, Vivianne C. G. Tjan-Heijnen, Carolien P. Schröder, Sabine C. Linn, Marleen Kok, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Epidemiology, and Medical Oncology

Subjects
EXPRESSION, Cancer Research, LOCALLY RECURRENT, Oncology, SDG 3 - Good Health and Well-being, CARCINOMA, FEATURES, MULTICENTER, SURVIVAL, CRITERIA, IMMUNOTHERAPY, CHEMOTHERAPY, SIGNATURES
Abstract

Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, but ILC-specific trials are lacking. Translational research revealed an immune-related ILC subset, and in mouse ILC models, synergy between immune checkpoint blockade and platinum was observed. In the phase II GELATO trial (NCT03147040), patients with metastatic ILC were treated with weekly carboplatin (area under the curve 1.5 mg ml–1 min–1) as immune induction for 12 weeks and atezolizumab (PD-L1 blockade; triweekly) from the third week until progression. Four of 23 evaluable patients had a partial response (17%), and 2 had stable disease, resulting in a clinical benefit rate of 26%. From these six patients, four had triple-negative ILC (TN-ILC). We observed higher CD8+ T cell infiltration, immune checkpoint expression and exhausted T cells after treatment. With this GELATO trial, we show that ILC-specific clinical trials are feasible and demonstrate promising antitumor activity of atezolizumab with carboplatin, particularly for TN-ILC, and provide insights for the design of highly needed ILC-specific trials.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results